Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that it ...

Wedbush upgrades Sarepta Therapeutics, citing overdone selloff and potential upside as FDA could re-approval Elevidys for non ...

After a challenging year for Sarepta Therapeutics, its chief executive has received his first equity grant in about eight ...

Sarepta Therapeutics (NASDAQ:SRPT) leads in genetic therapies, contributing to ongoing discussions surrounding the nasdaq ...

Wondering if Sarepta Therapeutics is a beaten down biotech bargain or a value trap? This article will walk through the numbers in plain English so you can decide with confidence. Despite a brutal long ...

Investing.com -- Sarepta Therapeutics (NASDAQ:SRPT) stock fell 8% on Thursday after the rare disease medicine specialist announced it would refinance approximately $291 million of its convertible ...

Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.

An announcement from Sarepta Therapeutics ( ($SRPT) ) is now available. On December 7, 2025, Sarepta Therapeutics‘ Board of Directors granted ...

Investing.com -- Sarepta Therapeutics Inc (NASDAQ:SRPT) stock fell 3.7% on Thursday after the company announced a debt exchange agreement that will restructure a portion of its convertible notes.

On November 25, 2025, Sarepta Therapeutics filed two petitions for inter partes review (“IPR”) challenging Genzyme’s patents relating to ...

Fintel reports that on December 9, 2025, Wedbush initiated coverage of Sarepta Therapeutics (NasdaqGS:SRPT) with a Outperform recommendation. Analyst Price Forecast Suggests 37.06% Upside As of ...

Dyne Therapeutics plans to submit its next-gen Duchenne muscular dystrophy drug to the FDA after a successful trial.